Summary
IDEXX Laboratories, Inc. reported revenue of $237.0 million for the third quarter of 2007, a 24% increase compared to the same period in the prior year. This growth was driven by strong performance across its segments, particularly the Companion Animal Group (CAG), and was bolstered by contributions from recent acquisitions. The company's gross profit margin saw a slight decrease to 48.2% from 51.8%, largely due to a $9.1 million inventory write-down related to the Navigator® product and a $1.0 million write-off of a prepaid royalty license. Operating income for the quarter declined by 12.3% to $32.5 million, impacted by increased operating expenses across segments, especially in CAG, which saw a rise in sales and marketing, general and administrative, and research and development costs. This increase in expenses was partly due to integrating acquired businesses and higher personnel-related costs. Despite the sequential dip in operating income, the company's balance sheet remains solid, with total assets increasing to $646.2 million. The company also continued its share repurchase program.
Key Highlights
- 1Total revenue increased by 24% year-over-year to $237.0 million in Q3 2007, driven by broad-based growth across all segments and acquisitions.
- 2Companion Animal Group (CAG) revenue grew by 24% to $194.0 million, with laboratory and consulting services showing significant 43.4% growth.
- 3Gross profit margin decreased to 48.2% from 51.8% in the prior year, primarily due to a $9.1 million inventory write-down for Navigator® product and a $1.0 million royalty license impairment.
- 4Operating income decreased by 12.3% to $32.5 million, with operating expenses increasing across most segments, reflecting investments in growth and integration of acquisitions.
- 5The company completed several acquisitions in early 2007, including Osmetech plc's Critical Care Division, Vita-Tech Canada Inc., Institut Pourquier SAS, and a veterinary reference laboratory in North Carolina, contributing to revenue growth.
- 6Cash and cash equivalents decreased to $49.6 million from $61.7 million at the beginning of the period, reflecting cash used in investing activities, including business acquisitions and capital expenditures.